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Background: Rheumatoid arthritis is a chronic inflammatory disease with a strong MHC class II component and
where many patients develop characteristic autoantibodies towards the noncoding amino acid citrulline. Such
anti-citrullinated protein antibodies (ACPA) have recently been put forward as an independent predictive factor
for treatment response by co-stimulation blockade by CTLA4-Ig (abatacept). We have performed a mechanism of
action study to dissect T cell functionality in RA patients with long-standing disease undergoing abatacept
treatment and the influence of ACPA status.
Results: Peripheral blood samples were collected from RA patients as they started CTLA4-Ig treatment and 3 and 6
months later. A general decrease of regulatory T cell subsets was observed in the cohort. Additionally within the
ACPA-positive group significant down-regulation of all key T cell effector subsets including Th1, Th2, and Th17 was
observed by analyzing cytokines by intracellular flow cytometry and in cell culture supernatants.
RA synovial fluid samples were cultured in vitro in the presence or absence of CTLA4-Ig (abatacept). T cell cytokine
production was diminished, but without increasing the functional capacity of CD4+CD25hi regulatory T cells as
previously demonstrated in the context of TNF-blockade and anti-IL6R therapy.
Conclusions: Our immunological study of T cell functionality in RA patients, both ACPA-positive and ACPA-negative,
starting biological therapy with the co-stimulation blockade abatacept (CTLA4-Ig) supports the recently published
registry study implicating ACPA seropositivity as an independent predictive factor to treatment response as we
observed the most striking effect on T cell subset modulation in ACPA-positive patients. These data further support
the notion of RA as a disease with several sub-entities, where the ACPA-positive fraction represents a classical
HLA-associated autoimmune disorder while ACPA-negative patients may have other driving forces apart from
classical adaptive immune responses.
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Rheumatoid arthritis (RA) is a systemic inflammatory
disorder characterized by chronic joint inflammation
and continuous cell infiltration into the synovium. The
presence of anti-citrullinated protein antibodies (ACPA)
in a large subset of patients supports the notion of an
autoimmune etiology and is tightly associated with the* Correspondence: vivianne.malmstrom@ki.se
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reproduction in any medium, provided the orHLA-DR shared epitope alleles, which suggests that
CD4+ T cells are important [1]. Indeed, CD4+ T cells
are abundant in both synovial tissue and in synovial
fluid. Furthermore, ACPA-positive RA patients develop
generally a more aggressive disease than ACPA-negative
patients [2,3].
The role of CD4+ T cells in RA pathophysiology may
be mediated through Th1 effector functions, mainly
IFN-γ secretion [4], Th17 activity or induction of ACPA
[5,6], leading finally to bone and cartilage destruction.
It has also been suggested that regulatory T cell (Treg)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and











Figure 1 ACPA level at baseline and 6 months following
abatacept treatment. ACPA level was measured in serum of 33 RA
patients undergoing abatacept therapy at baseline and 6 months
following treatment. Samples ≥ 25 AU/mL are defined as positive.
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http://www.biomedcentral.com/1471-2172/14/34function may be impaired in RA [7]. Tregs represent a
crucial T cell subset in the maintenance of immune
homeostasis and are significantly enriched in the syn-
ovial fluid of RA patients [8,9].
Commonly used biological therapies for RA target
mainly cytokine pathways, with the exception of the B
cell depleting agent rituximab and abatacept, a chimeric
CTLA4 and IgG Fc fusion protein modulating T cell acti-
vation. Abatacept is believed to work by blocking CD28
costimulation and thereby interfering with T cell-APC
interaction and limiting T cell activation. Use of abatacept
is associated with reduction in joint inflammation, pain
and joint damage in patients with active RA [10]. Recently
it has been reported that abatacept shows a better clinical
response in ACPA-positive as compared to ACPA-negative
patients [11]. Many lines of evidence suggest that the
CD4+ T cell compartment is more active in ACPA-positive
as compared to ACPA-negative RA.
In this study we compared T cell functionality in the
context of ACPA status in patients before and after T cell
costimulation blockade by abatacept. Our data demon-
strate that abatacept therapy significantly reduces circulat-
ing Treg frequencies, as well as effector cytokine output
from Th1, Th2 and Th17 cells in ACPA-positive patients,
but not in ACPA-negative patients. We further validated
these findings in synovial fluid cell cultures where pharma-
cological doses of abatacept were added. We conclude that
abatacept interferes with the full range of T cell subsets,
especially T cells in ACPA-positive patients.
Results
Unchanged levels of autoantibodies in abatacept-treated
patients
For this study 33 patients starting on abatacept therapy
were included and peripheral blood was collected at
baseline and after 3 and 6 months. It has recently been
reported that treatment with abatacept shows better results
in ACPA-positive individuals, and we therefore examined
both the ACPA status of our patient cohort at baseline and
investigated changes in ACPA levels from baseline to the 6
months follow-up.
In the cohort, 23 of 33 investigated patients had serum
antibodies against citrullinated proteins (Figure 1), but
we did not observe any significant changes in the ACPA
levels during the study period, nor did the ACPA status
predict clinical outcome; however this study was not
intended and powered to adequately address this issue.
Our aim instead was to investigate the adaptive immune
function.
Diminished T cell effector functions in patients treated
with abatacept
We started by investigating the most relevant cytokines
in the context of RA, namely IFN-γ, TNF and IL-17, asthey are all implicated in disease pathogenesis and are
central in Th1 and Th17 function.
At baseline and six months following abatacept therapy,
PBMCs from 19 patients were utilized for polyclonal T cell
stimulation for both 6 hrs and 5 days, and subsequently
intracellular cytokine stainings were performed. By this ap-
proach, each individual is its own control. Representative
flow cytometry stainings are depicted in Figure 2A. While
unstimulated cells did not produce cytokines, robust pro-
duction was observed following polyclonal stimulation
(Figure 2A).
Our data show that T cells of the Th1 subset from
ACPA-positive patients are clearly affected by abatacept, as
both TNF and IFN-γ production by CD4+ T cells were sig-
nificantly decreased at the day 5 read-out (Figure 2D). Only
minor secretion of IL-17A could be observed after poly-
clonal stimulation, but we still saw a tendency in dimin-
ished IL-17A production after treatment (Figure 2B and D).
In contrast, cells from ACPA-negative patients displayed
the opposite pattern with increased cytokine produc-
tion of TNF, IFN-γ and IL-17A (Figure 2C and E).
Our multiparameter flow approach allows a compari-
son of the different cytokines within each patient sample.
To this end we calculated ratios of each cytokine and
sample by comparing 6 months with baseline. Again, all
ACPA-negative patients showed higher ratios (>1), i.e. in-
creased expression while the ACPA-positive patients
mostly displayed reduced cytokine output (<1) (data not
shown). From these ratios we further determined the
spearman’s rank correlation coefficients for the different
cytokine combinations. A significant correlation between
all examined cytokines (IFN-γ/TNF: r=0.651, p=0.003;

































































































































































Figure 2 Flow cytometry staining for intracellular cytokines TNF, IFN-γ, IL-17A. PBMCs were stimulated in vitro with α-CD3 for 6 h or 5 days
and intracellular cytokine staining was performed for IFN-γ, TNF and IL-17A. The plotted cells are gated as CD14-CD3+CD4+CD28+ T cells. (A) A
representative FACS staining. Left row: Unstimulated cells. Subsequent rows: α-CD3 stimulation at baseline and 6 months following treatment.
(B-E) Intracellular cytokine stainings. (B) ACPA-positive patients, 6h stimulation (n=12). (C) ACPA-negative patients, 6h stimulation (n=7).
(D) ACPA-positive patients, 5days stimulation (n=12). (E) ACPA-negative patients, 5days stimulation (n=6).
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p=0.016) was detected demonstrating that the effect of
CTLA-Ig was general rather than biased.
Abatacept modulates key cytokines influencing different
T helper subsets
Abatacept limits the immune response by binding to
CD80 and 86 on antigen-presenting cells (APCs). Hence,
we investigated the immune-modulatory effect of abatacept
in the cell culture supernatants of polyclonal stimulated
PBMCs from 17 abatacept-treated patients by luminex and
a panel of 15 cytokines. We focused on cytokines relevant
for the Th1, Th2 and Th17 subsets.
In ACPA-positive patients IL-3, IL-13 and IL-23
were significantly diminished after abatacept treatment
(Figure 3). IL-2, -4, -7, -9, -10, -17A, -17F, -21, -22 and
TNF were also diminished, but the change did not reach
statistical significance. IL-1β levels tended to increase after
abatacept treatment in this patient group.
For ACPA-negative patients IFN-γ was significantly
increased (Figure 3). Many other examined cytokines
were also increased but without reaching statistical
significance.
Abatacept reduces regulatory T cell frequencies in vivo
Next we investigated the phenotype of Tregs in patients
undergoing abatacept therapy.
Polychromatic flow cytometry was performed on peri-
pheral blood samples of 12 RA patients taken at initiation
of treatment (0 months) and 3 months post-treatment.
In addition to FOXP3, we also investigated Helios, CD39and CTLA4 as they have been implicated in Treg func-
tion in RA [12-16], as well as CD45RA to also address
naïve Tregs.
A representative staining of FOXP3 expression be-
fore and after therapy is depicted in Figure 4A. A sig-
nificant reduction in the frequency of FOXP3+ Tregs,
Helios+ and CD39+ T cells was observed at 3 months
as compared to baseline (Figure 4B-D). To dissect this
further, we also analyzed the proportion of naïve thymus-
derived Tregs based on CD45RA expression in conjunc-
tion with FOXP3, the proportion of Th17-suppressive
Tregs based on CD39 expression, as well as the expres-
sion of the Treg effector molecule CTLA4. As shown
in Figure 4E-G, all Treg subsets were considerably re-
duced at the 3 month time point. For 4 of the included
patients, we also studied the Treg phenotype at 6
months and the decline in frequencies remained low,
suggesting that this is a general outcome of costimulation-
blockade and not a transient effect (Additional file 1:
Figure S1).
Abatacept reduces synovial T cell function in vitro
In rheumatoid arthritis, affected joints accumulate syn-
ovial fluid that often is very cellular with substantial
fractions of both effector/memory T cells and Tregs.
To assess whether abatacept would also influence T cell
functionality at the site of inflammation, we studied
the effect of in vitro added abatacept on both sy-
novial T effector and Treg function. By this approach
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Figure 3 Cytokines in cell culture supernatants. PBMCs were stimulated in vitro with α-CD3 for 5 days and supernatants were taken and
examined by the luminex method for 15 cytokines. Cytokine levels of 17 patients at baseline (non hatched bars) and post-treatment
(hatched bars). White bars represent ACPA-positive patients (n=10), whereas grey bars represent ACPA-negative patients (n=7).
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T cells in vitro by investigating suppression in the pres-
ence of abatacept. Treg co-culture experiments were
performed but no difference in suppressive capacity was
seen in cultures with abatacept compared to control
cultures (Figure 5A and B). However, we observed a signifi-
cant reduction of CD25-negative T effector cell prolifera-
tion in the presence of abatacept (Figure 5C).
Second, we studied the effects of abatacept on the whole
SFMC population using polyclonal and antigen-specific
stimulation. As depicted in Figure 5D, abatacept signifi-
cantly down-regulated the proliferative response following
polyclonal (n=15) and antigen-specific (n=7) stimulation.
We also observed reduced IFN-γ levels in the culture su-
pernatants of the abatacept-treated cells (data not shown).
The reduced proliferation was confined to the
autoantibody-positive fraction of the patients (Figure 5E
and F).
Discussion
Abatacept is a soluble chimeric CTLA4 protein, which
binds with high affinity to the B7 molecules CD80 andCD86 expressed on antigen-presenting cells. The out-
come of this blockade could be manifold, including
changes of activity and lifespan of APCs and limiting the
activation and re-activation of CD4+ T cells. In the
present study we demonstrate a significant down-
regulation of all key T cell effector subsets including
Th1, Th2 and Th17 by abatacept. We saw these effects
in the ACPA-positive patient subset, but not in the
ACPA-negative patients. Further, we could show a gen-
eral decrease in frequencies of regulatory T cells.
Today it is widely recognized that ACPA-positive and
ACPA-negative RA are distinct disease sub-entities as
these two phenotypes demonstrate major differences in
terms of HLA-association, other genetic and environ-
mental risk factors, clinical disease phenotype and treat-
ment response and probably in molecular pathogenesis
as well [17-21].
Clinical response to CTLA4-Ig (abatacept) can be differ-
ent early in disease as compared to patients with
established disease. It has also been shown that sero-
conversion (ACPA-positive turning into ACPA-negative) is
possible in early RA patients treated with abatacept
Figure 4 Treg frequency is diminished. PBMCs from baseline and 3 months following treatment (n=12) were obtained and multicolor flow
cytometry was performed. A general reduction in frequency of several Treg associated markers could be seen (A-G). (A) The graph depicts a
representative staining of CD4+FOXP3+ Treg before and after treatment. (B) The graph displays CD4+FOXP3+ Treg, (C) Helios+ T cells,
(D) CD4+CD39+ T cells, (E) CD45RA+FOXP3+ Treg, (F) CTLA4+ FOXP3+Treg, and (G) CD39+FOXP3+ Treg.
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abatacept may impact on autoantibody formation. How-
ever, we could not detect any difference in ACPA levels
after 6 months of treatment, but our cohort consists of pa-
tients with “long-standing” disease who have failed several
biologicals prior to starting with abatacept. Interestingly it
was recently published that in a cohort similar to ours (but
larger), ACPA status was an independent factor positively
correlating to therapy response, where ACPA-positive RA
patients responded better to Abatacept treatment than
ACPA-negative [11]. Still, abatacept is approved for use in
both ACPA-positive and ACPA-negative patients and pa-
tients in our study who demonstrated a clinical response
towards abatacept were both ACPA-positive and negative.
This illustrates how therapeutic progress is possible even
though the role of T cells in ACPA-positive vs. ACPA-
negative RA is not (fully) understood.
Importantly, our study aimed at dissecting the out-
come of costimulation blockade by abatacept on a cell
population level. It was not powered to address clinical
outcome or identify biomarkers for therapy response. In
particular the number of ACPA-negative patients in our
cohort was low, reflecting a typical RA cohort of patients
with long-standing disease.To address the question of which cells are affected by
abatacept therapy, we studied both peripheral blood
samples of patients undergoing therapy as well as synovial
fluid cells from disease-active joints where abatacept has
been added to the cultures. Recently another study focus-
ing on T helper cells in affected joints was published. Con-
sistent with our data, they showed that CTLA4-Ig leads to
reduced levels of proinflammatory cytokines IFN-γ and
IL-2 but they also reported increased levels of IL-10 and
TGF-β. ACPA status was not reported [24].
In our study we investigated cytokine production rep-
resentative for different T cell subsets (Th1, Th2, Th17),
utilizing PBMCs of abatacept-treated patients by two dif-
ferent methodological approaches. Strikingly, a reduction
in Th1, Th2 and Th17 cytokines in ACPA-positive pa-
tients was seen, but not in ACPA-negative patients. The
observed down-regulation of IFN-γ is supported by a
previous study by Cutolo et al. showing that abatacept
in vitro can decrease synovial macrophage activation
when co-cultured with T cells accompanied with a de-
creased production of proinflammatory cytokines such
as IL-6 and TNF [25]. A few years ago, Buch et al. inves-
tigated synovial biopsies from established RA and could
demonstrate a decrease of number of B cells after 16


























































































Figure 5 Abatacept reduces T cell proliferation in vitro. (A-C) SFMC from RA patients (n=6) were sorted into CD4+CD25- T effector cells as well as
CD4+CD25++ Treg and were co-cultured with CD3-APC for 6 days in the presence of plate-bound α-CD3, either in the presence or absence of 10 μg/ml
abatacept. (A) Synovial CD4+CD25- T effector cells were cultured alone and in the presence of different ratios of CD4+CD25++ Treg. The graph depicts
the percentage of suppression by CD4+CD25++ Treg in co-culture either in the absence (black line) or the presence of abatacept (grey line). A summary
of six experiments is shown and all values are expressed as mean+SD. (B) The graph displays the suppression of proliferation at the 1:1 ratio of T effector
cells and Tregs. (C) Proliferation of CD4+CD25- T effector cells alone was measured by thymidine incorporation in the absence or presence of abatacept
(n=6). (D-F) SFMC from RA patients were stimulated with α-CD3 (white bars) or influenza vaccine (grey bars) in the presence of 10 μg/ml abatacept or a
control compound. Proliferation of SFMC was measured by thymidine incorporation following 72 hours (α-CD3) or 6 days (influenza) in culture. All values
are expressed as mean+SD. (D) All patients are displayed, (α-CD3: n=15 patients; Influenza: n=7). (E) Only ACPA-positive patients are displayed, (α-CD3:
n=9 patients; Influenza: n=5). (F) Only ACPA-negative patients are displayed, (α-CD3: n=6 patients; Influenza: n=2).
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[26]. The ACPA status was not reported in these studies.
We also explored the regulatory T cell compartment
(Treg) since it is well established that optimal Treg func-
tionality is dependent on costimulation as antigen-specific
Tregs are the most efficient suppressor cells [27]. We have
recently shown that synovial Tregs proliferate in vivo [28],
suggesting that Tregs in the rheumatic joint interact with
their cognate antigens. In the same study, we also showed
that biological therapies targeting TNF and IL-6R could
lead to increased suppression by synovial Tregs [28]. This
is in line with studies performed on Tregs in the circula-
tion of RA patients [29,30]. However, we could not detect
increased suppressive capacity, even though the T effector
proliferation rate was reduced by abatacept. This observa-
tion supports the importance of costimulation for Treg
function. Thus, the clinical efficacy seen with abatacept is
not due to increased Treg functionality.The focus of the phenotype study was on natural Tregs
expressing the lineage marker FOXP3, and subsets thereof.
Overall we found a general reduction of FOXP3+ natural
Tregs in the periphery, supporting the data by Alvarez-
Quiroga et al, who demonstrated reduced Treg frequencies
based on FOXP3 and CD25 expression [31].Conclusion
Our study shows that abatacept has a significant impact
on T effector functions of the Th1, Th2 and Th17 sub-
sets and that effects were predominantly seen in the
ACPA-positive patient subset. Treg frequencies were di-
minished in the periphery, however no significant changes
in function were seen in synovial in vitro co-culture essays.
This data gives further evidence that RA has to be seen as
a disease with several different sub-entities, and supports
the view that ACPA-positive and ACPA-negative patients
Pieper et al. BMC Immunology 2013, 14:34 Page 7 of 9
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with repercussions for treatment strategies.
Methods
Patients and samples
Two cohorts of patients were collected: a first cohort
consisted of a total of 29 patients treated with abatacept.
Patients had a mean age of 55(18–74), 79% female
(n=23), 65% ACPA-positive (n=19). PBMCs and serum
from RA patients were collected at month 0, on initiation
of abatacept therapy, and after 3 months and 6 months
of therapy. Patients were treated with abatacept by intra-
venous infusion according to baseline weight (< 60 kg,
500 mg; 60–100 kg, 750 mg; and > 100 kg, 1000 mg) on
days 1, 15, 29, and then every 4 weeks. Clinical assessment
of the patients was performed after 3 and 6 months and
the clinical response was evaluated using the European
League Against Rheumatism (EULAR) response criteria,
based on the disease activity score using the 28 joint
count (DAS28) and erythrocyte sedimentation rate. The
second cohort consisted of 16 RA and 6 JIA patients,
from which Synovial fluid and serum was obtained.
(Mean age 51(23–86), 77% female (n=17), 50% ACPA-
positive (n=11)). All patients attended the Rheumatology
Clinic at Karolinska University Hospital. All RA patients
fulfilled the ACR criteria for RA [32].
Peripheral blood and synovial fluid samples prepared
by ficoll (Ficoll-Paque Plus, GE Healthcare, Uppsala,
Sweden) separation and cryopreserved until use. Serum
samples were stored at −70°C until use.
The ethics review board of the Karolinska University
Hospital approved this study, and all study subjects gave
informed consent according to the declaration of Helsinki.
Anti-CCP assay (ACPA)
Serum samples from 33 patients were used to determine
anti-citrullinated cyclic peptides (anti-CCP) levels using
the anti-CCP-2 ELISA kit (Immunoscan RA Mark 2; Euro-
Diagnostica, Arnhem, The Netherlands) according to the
manufacturer’s instructions.
Intracellular cytokine staining
Cells from 19 patients collected at 0 and 6 months after
abatacept treatment were cultured for 6h or 5 days in
complete media (RPMI, HEPES, L-Glutamine, Penicillin,
Streptomycin) containing 5% human serum and stimulated
with plate-bound α-CD3 monoclonal antibody (2.5 μg/ml,
clone OKT-3). All cultures were incubated at 37°C, 5%
CO2. Supernatants were collected on day 5 and stored
at −80°C until use.
In order to prevent produced cytokines from being se-
creted, 10 μg/ml Brefeldin A (Sigma-Aldrich, Steinheim,
Germany) was added to the cultures 4 h prior to harvesting.
Extracellular and intracellular cytokine staining wasperformed using Cytofix/Cytoperm Kit (BD) according to
the manufacturer’s instructions. Antibodies: α-CD28 PE
(clone: L293, BD), α-CD14 APC Cy7 (clone: MphiP9, BD),
α-CD4 PeCy7 (clone: SK3, BD), α-CD3 PB (clone:
UCHT1, BD and Biolegend), α-IFN-γ FITC (clone: B27,
BD), α-TNF PerCP Cy5.5 (clone: Mab11, Biolegend),
α-IL17 Alexa 647 (clone: BL168, Biolegend).
Beriglobin was added in order to prevent unspe-
cific staining and LIVE/DEAD Aqua Dead Cell Stain
(Invitrogen) was used to exclude dead cells. The PBMCs
were run on a Beckman Coulter CyAn. Analyses were
performed with FlowJo software, version 8.1.0 or higher
(Treestar Inc.).
Luminex analysis of cell culture supernatants
Cytokine analysis was performed on the collected super-
natant samples from the 5 day cultures using the multi-
plex assay LEGENDplex (Biolegend, San Diego, CA,
USA) and read on a Luminex100™ platform (Bio-Rad,
Hercules, CA, USA) with Bio-Rad software. The cyto-
kines analyzed were; interleukin IL-1β (1.9), IL-2 (0.3),
IL-3 (4.1), IL-4 (0.6), IL-7 (1.5), IL-9 (0.1), IL-10 (0.2),
IL-13 (0.2), IL-17A (0.7), IL-17F (1.6), IL-21 (0.2), IL-22
(4.4), IL-23 (1.2), TNF (0.6) and IFN-γ (0.2). Detection
limits for these cytokines/chemokines are indicated in
brackets in pg/ml.
Phenotypic characterization of Tregs
PBMCs taken from 12 patients at 0 and 3 months post-
treatment were utilized for phenotypic analyses by flow
cytometry. Intranuclear staining of FOXP3 and Helios was
performed using FOXP3/Transcription factor staining kit
(eBioscience, San Diego, CA, USA) according to the man-
ufacturer’s instructions. Antibodies: α-CD3 Alexa700
(clone: UCHT1, Biolegend), α-CD3 FITC (clone: UCHT1,
BD), α-CD4 PE (clone: RPA-T4, BD), α-CD39 FITC
(clone: A1, Biolegend), α-CD45RA ECD (clone:
2H4LDH11LDB9, Beckman Coulter), α-Helios Alexa647
(clone: 22F6, Biolegend), α-FOXP3 PB (clone: 206D,
Biolegend), α-CTLA4 PE (clone: BNI-3, BD). LIVE/DEAD
Near-IR Dead Cell Stain (Invitrogen) was used to exclude
dead cells. The PBMCs were run on a Beckman Coulter
Gallios (Beckman Coulter, Brea, CA, USA). Analyses were
performed with FlowJo software, version 8.1.0 or higher
(Treestar Inc., Ashland, OR; USA).
In vitro study of SFMC in the presence of abatacept
SFMC (n=16) were thawed and stimulated with either
plate-bound α-CD3 (1 μg/ml, clone: OKT-3) for 72 hours
or with influenza vaccine (Fluvirin vaccine 2001/2002,
Evans Vaccines Limited, Liverpool, UK) for 6 days. For
Treg suppression assays, SFMC (n=6) were thawed and
sorted by flow cytometry into CD3-APC, CD3+4+25- ef-
fector T cells and CD3+4+25++ Tregs and co-cultured
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days [28] in presence or absence of 10 μg/ml abatacept.
For total SFMC Abatacept or a control compound
(Chimeric L6 Bd2.1 IgG) was added at 10 μg/ml (both pro-
vided by Bristol-Myers Squibb, Princeton, NJ, USA), which
represents the physiological concentration in the blood of
patients post-treatment [33]. During the last 15–18 hours
of the incubation 3H-labelled thymidine (1uCi/well, Perkin
Elmer, Boston, MA, USA) was added to the wells and the
counts per minute were measured, indicating cell division.
Cytokines were measured in supernatants with the CBA
Inflammation Kit (Becton Dickinson (BD), San Jose, CA,
USA) according to the manufacturer’s instructions and
were acquired and analyzed with a FACS calibur (BD).Statistical analysis
A nonparametric Wilcoxon signed-rank test was used to
compare control and abatacept-treated SFMC cultures,
Treg co-cultures, Treg frequencies, and differences be-
tween baseline and post-treatment cytokine secretion
and cytokine levels. P values less than 0.05 were consid-
ered statistically significant. Spearman’s rank correlation
coefficient was used to analyze the ratio between differ-
ent combinations of cytokines.
All statistical analyses were performed using Prism 5.0
(GraphPad Software, La Jolla, CA, USA).Additional file
Additional file 1: Figure S1. Treg frequency is diminished. PBMCs
from baseline, 3 months and 6 months following treatment (n=4)
were obtained and multicolor flow cytometry was performed. A general
reduction in frequency of several Treg associated markers could be seen
(A-F). (A) The graph displays CD4+FOXP3+ Treg, (B) Helios+ T cells,
(C) CD4+CD39+ T cells, (D) CD45RA+FOXP3+ Treg, (E) CTLA4+ FOXP3+Treg,
and (F) CD39+FOXP3+ Treg.Competing interests
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